title: Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
abstract: In this paper, orally disintegrating tablets (ODT) were prepared using nanocrystal formulations in order to optimise dissolution properties of lipophilic, poorly soluble drug piroxicam (PRX). Different nanocrystal formulations were prepared using a high pressure homogenisation technique and poloxamer 188 as stabiliser. Characterisation of PRX nanocrystal ODT was carried out by infrared spectroscopy (FTIR), X-ray powder diffractometry (XRPD), differential scanning calorimetry and photon correlation spectroscopy. Dissolution study of PRX ODT was performed in distilled water (pH 5.5) and was compared to that of PRX coarse suspension ODT, PRX/poloxamer 188 physical mixture and bulk PRX samples. The XRPD and FTIR studies demonstrated that the homogenisation process led to a polymorphic transition from form I (bulk commercial PRX) to form III and monohydrate form of the nanocrystals. All ODT formulations prepared using PRX nanosuspensions showed a higher PRX dissolution rate compared with the ODT prepared with the coarse PRX. Since the solubility of the different PRX polymorphic forms increased only slightly from bulk PRX (form I) to monohydrate, form II and form III, we can conclude that the improvement in PRX dissolution rate is mainly caused by the increased surface-to-volume ratio due to the submicron dimension of the drug particles.
authors.affiliation: Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Cagliari, Cagliari, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Lai
authors.forename: E
authors.initials: E
authors.lastname: Pini
authors.forename: G
authors.initials: G
authors.lastname: Angioni
authors.forename: M L
authors.initials: ML
authors.lastname: Manca
authors.forename: J
authors.initials: J
authors.lastname: Perricci
authors.forename: C
authors.initials: C
authors.lastname: Sinico
authors.forename: A M
authors.initials: AM
authors.lastname: Fadda
mesh_terms: D000284:Administration, Oral; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D010894:Piroxicam / Q000008:administration & dosage* / Q000737:chemistry*; D020442:Poloxamer / Q000737:chemistry; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013535:Suspensions; D013607:Tablets; D014961:X-Ray Diffraction
chemical_list: D004337:Drug Carriers; D013535:Suspensions; D013607:Tablets; D020442:Poloxamer; D010894:Piroxicam